Universal regimens or universal access to drug susceptibility testing for tuberculosis?-Reference-Cited by-同舟云学术

Universal regimens or universal access to drug susceptibility testing for tuberculosis?

Published:2019-03 Issue:3 Volume:19 Page:224-225
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Acquah Rebecca,Furin Jennifer

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference9 articles.

1. Pan-tuberculosis regimens: an argument for;Wallis;Lancet Respir Med,2018

2. Report of the consensus meeting for finalization of target regimen profiles for TB treatment. July 7-8, 2016,2016

3. Better and safer treatment for multidrug-resistant tuberculosis;Farmer;Lancet,2018

4. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation;Caminero;Int J Tuberc Lung Dis,2008

5. Developing a human rights-based approach to tuberculosis;Citro;Health Hum Rights,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-day phenotypic drug susceptibility testing forMycobacterium tuberculosisvariantbovisBCG using single-cell imaging and a deep neural network;2024-05-20

2. Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform;Nature Communications;2024-03-18

3. Nanomotion technology in combination with machine learning: a new approach for a rapid antibiotic susceptibility test for Mycobacterium tuberculosis;Microbes and Infection;2023-09

4. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial;Trials;2022-10-08

5. Celebrating choice in the care of people living with drug-resistant tuberculosis;The Lancet;2022-10